Role of mitochondria in drug-induced hepatotoxicity;Role des mitochondries dans l'hepatotoxicite des medicaments

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 1, 1998, Pages 59-72

  Berson, Alain ^a   Fromenty, Bernard ^a   Lettéron, Philippe ^a   Pessayre, Dominique ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Aging; Beta oxidation; Cytokines; Drugs; Hepatitis; Hepatotoxicity; Hormones; Mitochondria; Mitochondrial DNA; Stea tosis; Steatohepatitis

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA INTERFERON; AMINEPTINE; AMIODARONE; COENZYME A; FIALURIDINE; GLUCOCORTICOID; MITOCHONDRIAL DNA; NONSTEROID ANTIINFLAMMATORY AGENT; PERHEXILINE; REACTIVE OXYGEN METABOLITE; SEX HORMONE; TETRACYCLINE; TIANEPTINE; VALPROIC ACID;

AGING; ALCOHOLISM; CYTOLYSIS; DNA REPLICATION; DNA TRANSCRIPTION; DRUG INDUCED DISEASE; FATTY ACID OXIDATION; FATTY LIVER; LIPID PEROXIDATION; LIVER TOXICITY; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; RESPIRATORY CHAIN; REVIEW; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; LIVER MITOCHONDRION; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PERMEABILITY; PHYSIOLOGY; TOXIC HEPATITIS;

ANIMALS; DNA REPLICATION; DNA, MITOCHONDRIAL; FATTY LIVER; HEPATITIS, TOXIC; HUMANS; LIPID PEROXIDATION; MITOCHONDRIA, LIVER; OXIDATION-REDUCTION; PERMEABILITY;

EID: 0031915534     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 1995;23 (suppl. 1): 16-24.
2. Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromcs P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997;26 (suppl 1):23-30.
3. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995;67:101-54.
4. Berson A, Renault S, Lettéron P, Robin MA, Fromenty B, Fau D, et al. Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction. Gastroenterology 1996;110:1878-90.
5. Pessayre D, Larrey D, Biour M. Drug-induced liver injury. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, eds. Oxford Textbook of Clinical Hepatology, 2nd ed. Oxford: Oxford University Press (sous presse).
6. Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol 1997;26 (suppl. 2):43-53.
7. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol 1997;26 (suppl. 1):13-22.
8. Watmough NJ, Bindoff LA, Birch-Machin MA, Jackson S, Bartlett K, Ragan CI, et al. Impaired mitochondrial β-oxidation in a patient with an abnormality of the respiratory chain. Studies in skeletal muscle mitochondria. J Clin Invest 1990;85:177-84.
9. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA 1994;91:10771-8.
10. Albring M, Griffith J, Attardi G. Association of a protein structure of probable membrane derivation with HeLa cell mitochondrial DNA near its origin of replication. Proc Natl Acad Sci USA 1977;74:1348-52.
11. Grosovsky AJ, De Boer JG, De Jong PJ, Drobetsky EA, Glickman BW. Base substitutions, frameshifts, and small deletions constitute ionizing radiation-induced point mutations in mammalian cells. Proc Natl Acad Sci USA 1988;85:185-8.
12. Cortopassi G, Wang E. Modelling the effects of age-related mtDNA mutation accumulation: complex I deficiency, Superoxide and death. Biochim Biophys Acta 1995;1271:171-6.
13. Kuchino Y, Mori F, Kasai H, Inoue H, Iwai S, Miura K, et al. Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and adjacent residues. Nature 1987;327:77-9.
14. Cortopassi GA, Shibata D, Soong NW, Arnheim N. A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. Proc Natl Acad Sci USA 1992;89:7370-4.
15. Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 1992;256:628-32.
16. Münscher C, Müller-Höcker J, Kadenbach B. Human ageing is associated with various point mutations in tRNA genes of mitochondrial DNA. Biol Chem Hoppe-Seyler 1993;374:1099-104.
17. Yen TC, Chen YS, King KL, Yeh SH, Wei YH. Liver mitochondrial respiratory functions decline with age. Biochem Biophys Res Commun 1989;3:994-1003.
18. Findor J, Perez V, Bruch Igurtua E, Giovanetti M, Fioravantti N. Structure and ultrastructure of the liver in aged persons. Acta Hepatogastroenterol 1973;20:200-4.
19. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science 1996;273:59-63.
20. Agarwal S, Sohal RS. DNA oxidative damage and life expectancy in houseflies. Proc Natl Acad Sci USA 1994;91:12332-5.
21. Orr WC, Sohal RS. Extension of life-span by overexpression of Superoxide dismutase and catalase in Drosophila melanogaster. Science 1994;263:1128-30.
22. Sohal BS, Agarwal A, Agarwal S, Orr WC. Simultaneous overexpression of copper and zinc-containing Superoxide dismutase and catalase retards age-related oxidative damage and increases metabolic potential in Drosophila melanogaster. J Biol Chem 1995;270:15671-4.
23. Lithgow GJ, Kirkwood BL. Mechanisms and evolution of aging. Science 1996;273:80.
24. Morgan MY, Sherlock S, Scheuer PJ. Acute cholesatsis, hepatic failure, and fatty liver in the alcoholic. Scand J Gastroenterol 1978;13:299-303.
25. Fromenty B, Grimbert S, Mansouri A, Beaugrand M, Erlinger S, Rötig A, et al. Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis. Gastrocntcrology 1995;108:193-200.
26. Mansouri A, Fromenty B, Berson A, Robin MA. Grimbert S, Beaugrand M, et al. Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholics. J Hepatol 1997;27:96-102.
27. Nordmann R, Ribière C, Rouach H. Implication of free radical mechanisms in ethanol-induced cellular injury. Free Rad Biol Med 1992;12:219-40.
28. Kukielka E, Dicker E, Cederbaum AI. Increased production of reactive oxygen species by rat liver mitochondria after chronic ethanol treatment. Arch Biochem Biophys 1994;309:377-86.
29. Wieland P, Lauterburg BH. Oxidation of mitochondrial proteins and DNA following administration of ethanol. Biochem Biophys Res Commun 1995;213:815-9.
30. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nature Med 1995;1:417-22.
31. Mitsuya H, Jarrett RF, Matsukura M, Veronese FDM, DeVico AL, Sarngadharan MG, et al. Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′,3′-dideoxynucleosides in vitro. Proc Natl Acad Sci USA 1987;84:2033-7.
32. Simpson MV, Chin CD, Keilbaugh SA, Lin TS, Prusoff WH. Studies on the inhibition of mitochondrial DNA replication by 3′-azido-3′-deoxythymidine and other dideoxynucleoside analogs which inhibits HIV-1 replication. Biochem Pharmacol 1989;38:1033-6.
33. Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2′,3′-dideoxyinosinc (ddI). Ann Intern Med 1991;115:283-4.
34. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;33:1099-105.
35. Richardson FC, Engelhardt JA, Bowsher RR. Fialuridine accumulates in DNA of dogs, monkeys and rats following long-term oral administration. Proc Natl Acad Sci USA 1994;91:12003-7.
36. Lewis W, Levine ES, Griniuviene B, Tankersley KO, Colacino JM, Sommadossi JP, et al. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA 1996;93:3592-7.
37. Shan B, Vazquez E, Lewis JA. Interferon selectively inhibits the expression of mitochondrial genes: a novel pathway for interferon-mediated responses. EMBO J 1990;9:4307-14.
38. Lewis JA, Huq A, Najarro P. Inhibition of mitochondrial function by interferon. J Biol Chem 1996;22:13184-90.
39. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
40. Deschamps D, Fisch C, Fromenty B, Berson A, Degott C, Pessayre D. Inhibition by salicylic acid of the activation and thus oxidation of long-chain fatty acids. Possible role in the development of Reye's syndrome. J Pharmacol Exp Ther 1991;259:894-904.
41. Starko KM, Mullick FG. Hepatic and cerebral pathology findings in children with fatal salicylate intoxication: further evidence for a causal relationship between aspirin and Reye's syndrome. Lancet 1983;1:328-9.
42. Waldman, RJ, Hall WN, McGee H, Van Amburg G. Aspirin as a risk factor for Reye's syndrome. JAMA 1982;247:3089-94.
43. Remington PL, Rowley D, McGee H, Hall WN, Monto AS. Decreasing trends in Reye's syndrome and aspirin use in Michigan, 1979 to 1984. Pediatrics 1986;77:93-8.
44. Rowe PC, Valle D, Brusilow SW. Inborn errors of metabolism in children referred with Reye's syndrome. A changing pattern. JAMA 1988;260:3167-70.
45. Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical, and histopathologic studies. Hepatology 1984;4:1143-52.
46. Rettie AE, Sheffels PR, Korzekwa KR, Gonzales FJ, Philpot RM, Baillie TA. CYP 4 isoenzyme specificity and the relationship between ω-hydroxylation and terminal desaturation of valproic acid. Biochemistry 1995;34:7889-95.
47. Kasahun K, Abbott F. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analogue 4-pentenoic acid. Drug Metab Dispos 1993;21:1098-106.
48. Fréneaux E, Labbe G, Lettéron P, Le Dinh T, Degott C, Genève J, et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988;8:1056-62.
49. Labbe G, Fromenty B, Fréneaux E, Morzelle V, Lettéron P, Berson A, et al. Effects of various tetracycline derivatives on in vitro and in vivo β-oxidation of fatty acids, egress of triglycerides from the liver, accumulation of hepatic triglycerides, and mortality in mice. Biochem Pharmacol 1991;41:638-41.
50. Deboyser D, Goethals F, Krack G, Roberfroid M. Investigation into the mechanism of tetracycline-induced steatosis: study in isolated hepatocytes. Toxicol Appl Pharmacol 1989;97:473-9.
51. Danan G, Trunet P, Bernuau J, Degott C, Babany G, Pessayre D, et al. Pirprofen-induced fulminant hepatitis. Gastroenterology 1985;89:210-3.
52. Dutertre JP, Bastides F, Jonville AP, de Muret A, Sonneville A, Larrey D, et al. Microvesicular steatosis after ketoprofen administration. Eur J Gastroenterol Hepatol 1991;3:953-4.
53. Fréneaux E, Fromenty B, Berson A, Labbe G, Degott C, Lettéron P, et al. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial β-oxidation of fatty acids. J Pharmacol Exp Ther 1990;255:529-35.
54. Genève J, Hayat-Bonan B, Labbe G, Degott C, Lettéron P, Fréneaux E, et al. Inhibition of mitochondrial β-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther 1987;242:1133-7.
55. Genève J, Larrey D, Amouyal G, Belghiti J, Pessayre D. Metabolic activation of the tricyclic antidepressant amineptine by human liver cytochrome P-450. Biochem Pharmacol 1987;36:2421-4.
56. Larrey D, Tinel M, Lettéron P, Maurel P, Loeper J, Belghiti J, et al. Metabolic activation of the new tricyclic antidepressant tianeptine by human liver cytochrome P-450. Biochem Pharmacol 1990;40:545-50.
57. Le Dinh T, Fréneaux E, Labbe G, Lettéron P, Degott C, Genève J, et al. Amineptine, a tricyclic antidepressant, inhibits the mitochondrial oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1988;247:745-50.
58. Fromenty B, Fréneaux E, Labbe G, Deschamps D, Larrey D, Lettéron P, et al. Tianeptine, a new tricyclic antidepressant metabolized by β-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice. Biochem Pharmacol 1989;38:3743-51.
59. Ramain JP, Labayle D, Buffet C, Chaput JC, Etienne JP. Hépatites à l'amineptine: 2 cas. Gastroenterol Clin Biol 1981;5:469-71.
60. Le Briquir Y, Larrey D, Blanc P, Pageaux GP, Michel H. Tianeptine. An instance of drug-induced hepatotoxicity predicted by prospective experimental studies. J Hepatol 1994;21:771-3.
61. Grimbert S, Fromenty B, Fisch C, Lettéron P, Berson A, Durand-Schneider AM, et al. Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to development of acute fatty liver of pregnancy. Hepatology 1993;17:628-37.
62. Grimbert S, Fisch C, Deschamps D, Berson A, Fromenty B, Feldmann G, et al. Effects of female sex hormones on liver mitochondria in non-pregnant female mice: possible role in acute fatty liver of pregnancy. Am J Physiol 1995;268:G107-15.
63. Wilcken B, Leung KC, Hammond J, Kamath R, Leonard JV. Pregnancy and fetal long chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency. Lancet 1993;341:407-8.
64. Mansouri A, Fromenty B, Durand F, Degolt C, Bernuau J, Pessayre D. Assessment of the prevalence of genetic metabolic defects in acute fatty liver of pregnancy. J Hepatol 1996;25:781.
65. Lettéron P, Brahimi-Bourouina N, Robin MA, Moreau A, Feldmann G, Pessayre D. Glucocorticoids inhibit mitochondrial matrix acyl-coenzyme A dehydrogenases and fatty acid β-oxidation. Am J Physiol 1997;272:G1141-50.
66. Kodavanti UP, Mehendale HM. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol Rev 1990;42:327-54.
67. Pessayre D, Bichara M, Feldmann G, Degott C, Potet F, Benhamou JP. Perhexiline maleate-induced cirrhosis. Gastroenterology 1979;76:170-7.
68. Guigui B, Perrot S, Berry JP, Fleury-Feith J, Martin N, Métreau JM, et al. Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology 1988;8:1063-8.
69. Fromenty B, Fisch C, Labbe G, Degott C, Deschamps D, Berson A, et al. Amiodarone inhibits the mitochondrial β-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1990;255:1371-6.
70. Fromenty B, Fisch C, Berson A, Lettéron P, Larrey D, Pessayre D. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 1990;255:1377-84.
71. Fromenty B, Lettéron P, Fisch C, Berson A, Deschamps D, Pessayre D. Evaluation of human blood lymphocytes as a model to study the effects of drugs on human mitochondria. Effects of low concentrations of amiodarone on fatty acid oxidation, ATP levels and cell survival. Biochem Pharmacol 1993;46:421-32.
72. Deschamps D, De Beco V, Fisch C, Fromenty B, Guillouzo A, Pessayre D. Inhibition by perhexiline of oxidative phosphorylation and the β-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology 1994;19:948-61.
73. Lettéron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic lipid steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1995;24:200-8.
74. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Rad Biol Med 1991;11:81-128.
75. Curzio M, Esterbauer H, Dianzani MU. Chemotactic activity of hydroxyalkenals on rat neutrophils. Int J Tiss Reac 1985;7:137-42.
76. Chojkier M, Houglum K, Solis-Herruzo J, Brenner DA. Stimulation of collagen gene expression by ascorbic acid in cultured human fibroblasts. J Biol Chem 1989;264:16957-62.
77. Houglum K, Brenner DA, Chojkier M. Inhibition of collagen gene expression by D-α-tocopherol in cultured human fibroblasts. J Clin Invest 1991;87:2230-5.
78. Bedossa P, Houglum K, Trautwein C, Holstege A, Chojkier M. Stimulation of collagen α1 (I) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis ? Hepatology 1994;19:1262-71.
79. Zatloukal K, Böck G, Rainer I, Denk H, Weber H. High molecular weight components are main constituents of Mallory bodies isolated with a fluorescence activated cell sorter. Lab Invest 1991;64:200-6.
80. Lettéron P, Duchatelle V, Berson A, Fromenty B, Fisch C, Degott C, et al. Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol abusers. Gut 1993;34:409-14.
81. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
82. Woolf TF, Pool WF, Bjorge SM, Chang T, Goel OP, Purchase II CF, et al. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference. Drug Metab Dispos Biol Fate Chem 1993;21:874-82.
83. Viau CJ, Curren RD, Wallace K. Cytotoxicity of tacrine and velnacrine metabolites in cultured rat, dog and human hepatocytes. Drug Chem Toxicol 1993;16:227-39
84. Fontana RJ, Turgeon DK, Woolf TF, Knapp MA, Foster NL, Watkins PB. The cafeine breath test does not identify patients susceptible for tacrine hepatotoxicity. Hepatology 1996;23:1429-35.
85. Green VJ, Pirmohamed M, Kitteringham NR, Knapp MJ, Park BK. Glutathione S-transferase m genotype (GSTMI*0) in Alzheimer's patients with tacrine transaminitis. Br J Clin Pharmacol 1995;39:411-5.
86. Berson A, Wolf C, Berger V, Fau D, Chachaty C, Fromenty B, et al. Generation of free radicals during the reductive metabolism of the nitroaromatic compound, nilutamide. J Pharmacol Exp Ther 1991;257:714-9.
87. Fau D, Berson A, Eugène D, Fromenty B, Fisch C, Pessayre D. Mechanism for the hepatotoxicity of the anti-androgen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. J Pharmacol Exp Ther 1992;263:69-77.
88. Berson A, Schmets L, Fau D, Wolf C, Fromenly B, Deschamps D, et al. Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen. J Pharmacol Exp Ther 1994;270:167-76.
89. Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Eugène D, et al. Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and IA subfamilies. J Pharmacol Exp Ther 1993;265:366-72.
90. Fau D, Eugène D, Berson A, Lettéron P, Fromenty B, Fisch C, et al. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 1994;269:954-62.
91. Meyers LL, Beierschmitt WP, Khairallah EA, Cohen SD. Acetaminophen-induced inhibition of hepatic mitochondrial respiration in mice. Toxicol Appl Pharmacol 1988;93:378-87.
92. Strubelt O, Younes M. The toxicological relevance of paracetamol-induced inhibition of hepatic respiration and ATP depletion. Biochem Pharmacol 1992;44:163-70.
93. Martin FL, McLean AEM. Comparison of protection by fructose against paracetamol injury with protection by glucose and fructose-1,6-diphosphate. Toxicology 1996;108:175-84.
94. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995;1241:139-76.
95. Zamzani N, Susin SA, Marcheti P, Hirsch T, Gomez-Monterrey I, Castedo M, et al. Mitochondrial control of apoptosis. J Exp Med 1996;183:1533-44.
96. Trost LC, Lemasters JJ. The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury. J Pharmacol Exp Thcr 1996;278:1000-5.